<DOC>
	<DOCNO>NCT01011621</DOCNO>
	<brief_summary>Topical corticosteroid largely used dermatology . The major problem relate use mechanism underlie therapeutic effect ( antiinflammatory antiproliferative ) may lead adverse event . Conditions sensitive corticosteroid require formulation mild moderate potency high-potency corticosteroid era require less responsive condition . The aim present study compare safety efficacy prednisolone acetate 0.5 % cream ( mild-potency non-fluoridated corticosteroid ) versus betamethasone valerate 0.1 % cream ( high-potency fluoridate corticosteroid ) treatment mild moderate cortisosensitive dermatosis ( atopic dermatitis , contact dermatitis , seborrheic dermatitis psoriasis ) . The study hypothesis 0.5 % prednisolone cream effective 0.1 % betamethasone cream alternative option treat corticosensitive dermatosis body area use fluoridated corticosteroid contraindicate , face .</brief_summary>
	<brief_title>Efficacy Tolerability Prednisolone Acetate 0.5 % Cream Versus Betamethasone Valerate 0.1 % Cream Cortisosensitive Dermatosis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<mesh_term>Skin Diseases</mesh_term>
	<mesh_term>Dermatitis , Contact</mesh_term>
	<mesh_term>Dermatitis , Seborrheic</mesh_term>
	<mesh_term>Betamethasone benzoate</mesh_term>
	<mesh_term>Betamethasone-17,21-dipropionate</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Betamethasone</mesh_term>
	<mesh_term>Betamethasone Valerate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Betamethasone sodium phosphate</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>Subjects corticosensitive dermatosis ( atopic dermatitis , contact dermatitis , seborrheic dermatitis , psoriasis ) mild moderate intensity ; Compliance subject treatment protocol ; Agreement term inform consent participant Subjects use follow medicine inclusion : topical corticosteroid therapy dermatitis ( 30 day ) ; oral corticosteroid ( 180 day ) ; parenteral corticosteroid ( 180 day ) ; immunomodulators/immunosuppressor ( 30 day ) ; drug investigation ( 1 year ) ; therapy study clinical condition ( 180 day ) ; keratolytic agent ( 30 day ) ; emollient agent ( 30 day ) ; tazarotene ( 30 day ) ; vitamin D ( topical oral , 30 day ) ; methotrexate ( 30 day ) ; acitretin ( 2 year ) ; UV light ( 30 day ) ; PUVA therapy ( 30 day ) . Exclusion criterion : Pregnancy risk pregnancy Lactation History allergy component formulation Other condition consider investigator reasonable noneligibility HIV positivity Drug abuse Subjects without previous response topical corticosteroid Subjects intense sun exposure within 15 day screen</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>November 2009</verification_date>
	<keyword>Prednisolone acetate</keyword>
	<keyword>Betamethasone valerate</keyword>
</DOC>